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BACKGROUND:We examined the associations between accelerometry-measured physical activity (PA) and incidence of 13 cancers
among a cohort of postmenopausal women.
METHODS: In this prospective study, 6382 women wore ActiGraph GT3X+ accelerometers at the hip for up to 7 days during
2012–2013, and were followed over a median of 4.7 years for diagnosis of 13 invasive cancers. Calibrated intensity cut points were
used to define minutes per day of total, light and moderate-to-vigorous PA. We used multivariable Cox regression to estimate
hazard ratios (HRs) and 95% confidence intervals (CIs) for tertiles, and one-standard deviation (SD) unit increments of PA exposures
in relation to cancer incidence. We examined effect measure modification by age, race/ethnicity, body mass index and smoking
history.
RESULTS: The highest (vs. lowest) tertiles of total, light and moderate-to-vigorous PA were associated with covariate-adjusted HRs of
0.72 (95% CI= 0.53–0.97), 0.81 (95% CI= 0.60–1.09) and 0.66 (95% CI= 0.48–0.91), respectively. In age-stratified analyses, HRs for
total PA were lower among women <80 years (HRper one-SD= 0.75, 95% CI= 0.63–0.90) than among women ≥80 years (HRper one-SD=
0.99, 95% CI= 0.82–1.18) (PInteraction= 0.03). Race/ethnicity, BMI and smoking did not strongly modify these associations.
CONCLUSIONS: Engaging in physical activity may play a beneficial role in the prevention of certain cancers in older women.
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BACKGROUND
Cancer is the second leading cause of death among women in the
United States (US).1 In 2019, ~890,000 women will be diagnosed
with invasive cancer, including 268,000 with breast cancer.2
Furthermore, shifting population demographics has led to a
greater number of adults aged 65 and older,3 and thus an
increased number of cancer patients and survivors, and growing
cancer care expenditures.4 Given the high burden of cancer in the
US, prevention is a significant public health issue.
More than half of the newly diagnosed cancer cases are
considered preventable through lifestyle modifications, vaccina-
tions and better implementation of clinical screening guidelines.5
Lifestyle factors, such as physical inactivity, are important
contributors to the incidence of cancer.6 Although the exact
biological mechanisms continue to be elucidated, it has long been
hypothesised that physical activity (PA) may play an important role
in cancer prevention by favourably impacting metabolic and
hormonal pathways, and optimising physiologic and immunologic
function in the human body, among other benefits.7 Numerous
epidemiologic studies have shown that individuals who self-report
higher levels of leisure-time PA have an overall lower risk of
developing8 and dying from cancer.9 However, the benefits of PA
for primary prevention appear to vary by cancer type. In a pooled
analysis of 1.44 million adults from 12 prospective US and
European cohorts, Moore et al. examined the relationship between
leisure-time PA and incidence of 26 site-specific cancers, and
reported that regularly engaging in higher levels of moderate-to-
vigorous physical activity (MVPA) was associated with lower risk of
13 cancers; relative risks reported ranged from 0.58 for oesopha-
geal adenocarcinoma to 0.90 for breast cancer.10 As noted by
Moore et al., prospective cohort studies of PA and cancer incidence
have largely relied on self-reported measures of PA.10 While self-
reported assessment of PA is relatively inexpensive and easily
employed in large epidemiologic studies, self-reported PA may
result in measurement error, thus potentially biasing risk estimates,
underscoring the need for using objective methods of PA
measurement when feasible.11,12
In this study, we examined the association between PA assessed
by accelerometry and incidence of 13 cancers previously shown to
be associated with PA,10 among postmenopausal women partici-
pating in the Women’s Health Initiative (WHI) Objective Physical
Activity and Cardiovascular Health (OPACH) Study.13 Furthermore,
we examined effect measure modification by age, race/ethnicity,
body mass index and smoking history, given the lack of available
evidence on the association between accelerometry-measured PA
and cancer incidence by these subgroups.14
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METHODS
Study population
The OPACH study, an ancillary to the Women’s Health Initiative
(WHI), is a prospective investigation of accelerometer-measured
PA and chronic disease outcomes among 7048 postmenopausal
women aged 63–99 years who were originally enrolled in the WHI
Long Life Study. Details of OPACH participant recruitment,
enrolment and study procedures have been reported previously.13
In this study, from the 7048 women enrolled, we excluded 327
women who did not return an accelerometer, 232 women who
returned accelerometers with unusable data and 107 women who
did not meet our criteria for adherence, which was having at least
1 day with at least 10 h of awake accelerometer wear time, the
conventional standard for compliant wear, as described below.
These exclusions resulted in an analytic sample of 6382 women. Of
these, the majority (97.6%) had ≥3 adherent days (mean= 6.3,
median= 7.0 days). At OPACH baseline, women had a mean age
of 78.7 years (SD= 6.7 years) and a mean BMI of 28.2 kg/m2.
The majority of women were well-educated as 79.7% reported
attending college or receiving a college degree, and 49.4% self-
reported their race/ethnicity as non-Hispanic white, as pre-
viously reported.13,15 All study protocols were approved by Fred
Hutchinson Cancer Research Center Institutional Review Board,
and all women gave written informed consent.
Cancer incidence
Cancer incidence was defined as a composite outcome variable
that included 13 site-specific fatal and non-fatal invasive cancers
previously shown to be inversely associated with MVPA in a
general population of adults including oesophageal, liver, lung,
kidney, gastric, endometrial, leukaemia, multiple myeloma, colon,
head and neck, rectal, bladder and breast cancers.10 Physician-
adjudicated cancer diagnosis was ascertained from enrolment in
2012–2013 through March 31, 2018, by ongoing surveillance
in the national WHI program using annual mailed health updates,
reports by family or friends, review of medical records, obituaries
and linkage to the National Death Index. We censored follow-up
time on the date of PA-related cancer diagnosis, the date of death
from an event unrelated to cancer or the date of last contact.
Excluding women with a cancer diagnosis prior to OPACH baseline
would prevent the assessment of how PA is associated with
the first-time occurrence of previously undiagnosed cancers, an
important public health question given the large number of older
adults with prevalent cancer. To assess whether having a previous
cancer diagnosis impacted the results, we performed sensitivity
analyses that excluded women with a history of cancer diagnosis
at OPACH baseline (n= 1071). History of cancer diagnosis at WHI
enrolment (1993–1998) was assessed by self-report, and at OPACH
baseline, history of cancer between WHI enrolment and OPACH
baseline was assessed by self-reports that were adjudicated by
physicians using medical record review.
Physical activity
PA was measured using the ActiGraph GT3X+ triaxial acceler-
ometer. Participants were instructed to wear the accelerometer at
their right hip during all waking hours, except when bathing or
swimming, and while sleeping, for 7 days. Data measured at 30 Hz
were aggregated to 15-s epochs using the normal filter in ActiLife
software (v6), and the three axes were converted into a measure
of the vector magnitude that was used to operationalise activity
intensity.16 A commonly used computer-based automated algo-
rithm was used to determine accelerometer wear time with
a window of 90 min, a streamframe of 30min and a tolerance of
2 min.17 Times that the participants were out of bed were
determined by using data from sleep logs completed for each
night of accelerometer wear.17 Missing sleep log data were
imputed using person-specific means, if available, or the sample
mean. Previously calibrated16 cut points were then used to assess
total PA (defined as movement resulting in energy expenditure
≥1.6 METs, the cut point for sedentary behaviour), light PA
(movement resulting in energy expenditure between 1.6 and
2.9 METs) and MVPA (movement resulting in energy expenditure
≥3.0 METs). Total PA was then measured as the average minutes
per day with accelerometer counts per 15 s of ≥19. Light PA and
MVPA were measured as the average minutes per day with
accelerometer counts per 15 s of 19–518 and ≥519, respectively.
Covariates
Information regarding baseline covariates was collected using
self-report questionnaires and anthropometric measurements
from an in-home clinical examination. Covariates included awake
accelerometer wear time (hours per day), age (continuous in
years), race/ethnicity (non-Hispanic white, non-Hispanic black and
Hispanic), education level (high school or less, some college
and college graduate), a composite measure of smoking status
and pack-years (never smoker, former smoker/≤7.5 or >7.5 pack-
years and current smoker/≤22.5 or >22.5 pack-years), frequency of
alcohol intake (non-drinker, <1, 1–4 and 5–7 drinks per week),
measured height and weight to calculate body mass index (BMI, in
kg/m2), hormone therapy use (no, yes), self-rated health status
(excellent or very good, good, fair or poor), number of chronic
conditions including history of coronary heart disease, stroke,
diabetes mellitus, osteoarthritis, depression, chronic obstructive
pulmonary disease, cognitive impairment, frequent falls, hearing
loss or visual impairment (none, 1–2 and 3+), diet quality assessed
using the Health Eating Index (HEI) 2010 (quartiles, with higher
quartiles indicating greater intake of foods that align with key
dietary recommendations)18,19 and history of cancer diagnosis
(no, yes).
Statistical analysis
We standardised the minutes of total, light and moderate-to-
vigorous PA for differences in wear time using the residuals
obtained when regressing each PA variable on wear time, and
then created tertiles of wear time-standardised PA variables for
use in statistical analyses.20–22 Cut points used to define tertiles
were ≤292.20, 292.21–371.34 and >371.34 min per day for total
PA; ≤251.76, 251.77–315.02 and >315.02 min per day for light PA;
≤30.83, 30.84–57.52 and >57.52 min per day for MVPA.
We used Kaplan–Meier survival curves to inspect the unad-
justed associations between tertiles of total, light and moderate-
to-vigorous PA with the composite incident PA-related cancer
outcome. We examined Schoenfeld residuals to assess the
proportional hazards assumption. There were no appreciable
violations of the proportional hazards assumption when we
compared the survival curves for the highest and lowest tertiles
of PA. We used Cox regression to estimate hazard ratios (HRs)
and 95% confidence intervals (CIs) for tertiles of total, light
and moderate-to-vigorous PA in association with incidence of
invasive cancer. We also examined linear trends (i.e., PTrend) using
continuous minutes of wear time-standardised PA. Cox regres-
sion models were first adjusted for age (Model 1). We then
included additional adjustment for race/ethnicity, education,
smoking status, hormone replacement use, self-assessed health
status and number of comorbidities (Model 2). Last, we included
adjustment for BMI (Model 3), a presumed mediator of the
association between PA and cancer incidence.
We used imputation to account for missing covariate data.
Variables with high proportions of missing values included HEI-
2010 (21.9% missing), alcohol use (16.3% missing) and smoking
status/pack-years (12.3% missing). We imputed missing values
using SPSS, which employs a fully conditional specification
algorithm, an iterative Markov Chain Monte Carlo procedure that
sequentially imputes missing values.23 SPSS applies logistic or
multinomial logistic regression to categorical variables, and linear
regression to continuous-scale variables. We used 25 imputations
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with 500 iterations, and included sociodemographic (age and race/
ethnicity, education and income), lifestyle and behavioural factors
(smoking status, smoking pack-years, alcohol use, body mass index,
hormone therapy use and HEI-2010), health characteristics (self-
rated health, number of comorbid conditions and history of cancer),
wear time-standardised minutes of total, light and moderate-to-
vigorous PA, the cancer event indicator and the Nelson–Aalen
estimator of the cumulative hazard.24 In sensitivity analyses, we also
excluded women who were diagnosed or censored within 6 months
of follow-up, and examined the associations between PA and
overall cancer incidence. We also examined whether our composite
measure of cancer was robust to the range of cancers included by
removing each of the 13 site-specific cancers at a time in fully
adjusted models examining the PA measures continuously. Last, we
used multivariable Cox regression isotemporal substitution models
to estimate the effect of statistically replacing time from one activity
for an equal amount of time from another activity. As reported in
the isotemporal literature,25–28 we first divided continuous minutes
of sedentary time, light PA and MVPA by 30, so that a unit increase
in sedentary behaviour or activity represented an increase of 30min
per day within the given category. We then entered all variables
that characterise total activity wear time and total wear time into a
single model, and sequentially dropped each one of the activity
variables.
In addition to examining PA tertiles, we analysed PA continuously
per standard deviation unit increments according to the overall
cohort, and a priori strata of interest defined by age (<80 vs.
≥80 years), race/ethnicity (white, black and Hispanic), BMI (<30 vs.
≥30 kg/m2) and smoking history (ever vs. never smoker). Tests for
multiplicative interaction were evaluated using likelihood ratio tests
comparing the fully adjusted Cox regression models with cross-
product terms for continuous PA and each of the categorical
covariates, with the reduced model without the interaction terms.
All statistical analyses were performed using IBM SPSS Statistics
Version 26 (IBM Corp., Armonk, NY).
RESULTS
Over a median follow-up of 4.7 years (max= 6.0 years), among the
6382 women in the cohort there were 1188 incident cancers, of
which 272 were PA-related. This included 99 invasive breast
cancers, 52 lung cancers, 33 colorectal cancers, 20 leukaemias, 17
bladder cancers, 16 myelomas, 10 endometrial cancers, 7 kidney
cancers, 6 liver cancers, 5 stomach cancers, 5 head and neck
cancers and 2 oesophageal cancers. Approximately 2.7% of
women (n= 171) in this cohort were lost to follow-up, and were
censored for lack of outcome data with partial follow-up. At
baseline, the women engaged in a mean 334.1 (SD= 90.8) min
per day of total PA, including a mean 284.4 (SD= 72.8) min
per day of light PA, and 49.7 (SD= 33.3) min per day of MVPA.
Overall, women with higher versus lower levels of wear time-
standardised total PA were younger, and had lower BMI and
higher levels of alcohol intake, self-rated general health and diet
quality, and had no history of cancer diagnosis (Table 1).
As shown in Table 2, incident PA cancer HRs declined in a
dose–response pattern across increasing tertiles of total PA.
Women with the highest (vs. lowest) tertiles of total PA had a HR
of 0.72 (95% CI= 0.53–0.97) in Model 2 (PTrend= 0.03). Additional
adjustment for BMI slightly attenuated this association (Model 3
HR= 0.76, 95% CI= 0.55–1.04, PTrend= 0.10). The inverse associa-
tion between PA and cancer incidence was more pronounced
when we considered MVPA. The highest (vs. lowest) tertile of
MVPA was associated with a HR of 0.66 (95% CI= 0.48–0.91) in
Model 2 (PTrend= 0.03), with some attenuation in the HR after BMI
adjustment (Model 3 HR= 0.69, 95% CI= 0.50–0.95, PTrend= 0.05).
Patterns of association for light PA were similar to those of MVPA;
however, estimates for light PA were closer to the null.
In Table 3, we present the results for PA-related cancer
incidence and continuous PA per one-standard deviation (SD)
unit increments of total, light and moderate-to-vigorous PA for the
overall cohort, and stratified by age, race/ethnicity, BMI and
smoking history. Among women <80 years, a one-SD unit increase
in total PA was associated with a multivariable HR of 0.75 (95%
CI= 0.63–0.90); however, this association was null among women
≥80 years (HR= 0.99, 95% CI= 0.82–1.18) (PInteraction= 0.03). This
interaction was also evident for light PA in which the HR among
women <80 years was 0.78 (95% CI= 0.65–0.93) and 1.01 (95%
CI= 0.85–1.20) among women ≥80 years (PInteraction= 0.04), but
less apparent for MVPA (PInteraction= 0.31). There was a suggestion
of effect measure modification by smoking history for MVPA and
PA-related cancer incidence (PInteraction= 0.09), with a stronger
inverse association among never smokers (HR= 0.76, 95% CI=
0.61–0.96) than among ever smokers (HR= 0.89, 95% CI=
0.74–1.08) (Table 3). Race/ethnicity and BMI did not modify these
associations.
We conducted several sensitivity analyses to examine the
robustness of our findings reported here. Excluding women with a
cancer diagnosis prior to OPACH enrolment (Supplementary
Table 1), and excluding those who were diagnosed or censored
within 6 months of follow-up (Supplementary Table 2), resulted in
no appreciable differences in the HR estimates. In analyses in
which we considered overall cancer incidence as the outcome,
age-only adjusted associations were generally greater in magni-
tude for all physical activity categories. The HRs were, however,
closer to the null with additional covariate adjustment than those
in which we used PA-related cancer incidence as the outcome
(Supplementary Table 3). The results for total PA, light PA and
MVPA were similar to the overall results when we excluded each
of the cancer sites at a time from the composite measure; the
largest changes in the estimates (6–8%) were observed when we
excluded lung cancers, with some loss in precision (Supplemen-
tary Table 4). Last, the results of the isotemporal substitution
models indicated that replacing 30min per day of sedentary time
with 30 min of light PA or MVPA was associated with HRs of PA-
related cancer incidence of 0.97 (95% CI= 0.92–1.03) and 0.89
(95% CI= 0.78–1.02), respectively.
DISCUSSION
In this large cohort study of postmenopausal women, examining
accelerometer-measured PA, higher levels of total PA and, in
particular, MVPA, were associated with reduced risk of 13 site-
specific cancers. The mean estimate of MVPA in this study (50 min
per day), while higher than that reported in the Women’s Health
Study (mean= 28min per day),29 was similar to the estimate
reported in the British Heart Study (mean= 39min per day)30 and
lower than that reported in a validation study of accelerometer-
measured PA in older adults (mean= 68min per day).31 Although
less pronounced and not statistically significant, the highest versus
lowest tertile of light PA was also inversely associated with
incidence of the 13 cancers of interest. Furthermore, the inverse
associations for total and light PA with cancer incidence appeared
to be stronger in women less than 80 years old as compared with
women over 80 years; however, the association between MVPA
and cancer incidence was not different in younger compared with
older women.
Over the past decade or so, epidemiologic studies have utilised
sensor devices (e.g., accelerometers) to quantify total and intensity-
specific PA more accurately and comprehensively than is possible
by questionnaire assessments.32 Associations with cardiometabolic
risk factors, all-cause and cardiovascular mortality outcomes
have been published frequently. In a previous OPACH study,
accelerometer-measured PA was not clearly associated with total
cancer mortality (87 deaths over a mean 3.1-year follow-up).15 This
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Table 1. OPACH participant baseline characteristics by tertiles of wear time-standardised total physical activity.
Characteristic Total PA minutes per day mean (SD) Tertiles of total PA
T1 (low) n (%) T2 n (%) T3 (high) n (%)
N 6382 2,125 2,126 2,131
Age (years)
60–69 369.8 (88.2) 127 (6.0) 213 (10.0) 314 (14.7)
70–79 348.9 (90.5) 692 (32.6) 856 (40.3) 1009 (47.3)
80–89 317.1 (87.4) 1162 (54.7) 972 (45.7) 772 (36.2)
≥90 288.2 (79.5) 144 (6.8) 85 (4.0) 36 (1.7)
Race/ethnicity
Non-Hispanic white 318.4 (89.5) 1266 (59.6) 1039 (48.9) 845 (39.7)
Non-Hispanic black 341.9 (88.9) 636 (29.9) 736 (34.6) 779 (36.6)
Hispanic/Latina 364.0 (89.2) 223 (10.5) 351 (16.5) 507 (23.8)
Highest education level
High school or less 337.0 (90.3) 409 (19.4) 420 (20.0) 460 (21.6)
Some college 329.7 (91.4) 875 (41.5) 810 (38.5) 771 (36.3)
College graduate or more 337.2 (90.7) 826 (39.1) 873 (41.5) 895 (42.1)
Missing 15 23 5
Smoking status and pack-years
Never 336.7 (90.17) 996 (54.2) 1077 (57.6) 1067 (56.5)
Former
≤7.5 pack-years 342.0 (90.43) 337 (18.3) 393 (21.0) 426 (22.6)
>7.5 pack-years 325.7 (91.74) 435 (23.7) 350 (18.7) 356 (18.9)
Current
≤22.5 pack-years 324.0 (85.42) 30 (1.6) 34 (1.8) 20 (1.1)
>22.5 pack-years 291.7 (83.98) 41 (2.2) 17 (0.9) 19 (1.0)
Missing 286 255 243
Alcohol intake in the past 3 months
Non-drinker 329.9 (89.5) 681 (41.0) 666 (36.8) 618 (33.1)
<1 drink per week 334.1 (89.8) 598 (36.0) 646 (35.7) 601 (32.2)
1–4 drinks per week 353.3 (87.3) 235 (14.1) 310 (17.1) 392 (21.0)
5–7 drinks per week 355.4 (92.3) 149 (9.0) 187 (10.3) 257 (13.8)
Missing 462 317 263
Body mass index (kg/m2)
<18.5 381.5 (96.5) 14 (0.7) 24 (1.2) 43 (2.1)
18.5–24.9 363.2 (91.3) 414 (21.1) 581 (29.2) 850 (42.1)
25.0–29.9 335.2 (84.3) 681 (34.8) 773 (38.8) 702 (34.7)
30.0–34.9 312.4 (85.2) 473 (24.1) 392 (19.7) 290 (14.3)
35.0–39.9 301.9 (87.2) 240 (12.3) 146 (7.3) 105 (5.2)
≥40.0 283.3 (82.4) 137 (7.0) 76 (3.8) 31 (1.5)
Missing 166 134 110
Self-rated general health
Excellent or very good 347.2 (90.7) 888 (42.0) 1071 (50.6) 1237 (58.3)
Good 325.2 (87.6) 938 (44.3) 852 (40.2) 740 (34.9)
Fair or poor 303.1 (92.1) 289 (13.7) 195 (9.2) 146 (6.9)
Missing 10 8 8
Number of chronic conditions
0 355.2 (92.1) 275 (13.0) 356 (16.8) 474 (22.3)
1 342.9 (89.7) 635 (30.0) 734 (34.7) 781 (36.8)
2 330.0 (87.8) 594 (28.1) 578 (27.4) 534 (25.2)
≥3 308.8 (89.0) 611 (28.9) 445 (21.1) 334 (15.7)
Missing 10 13 8
Any hormone replacement therapy
No 333.2 (90.8) 2094 (98.5) 2072 (97.5) 2054 (96.4)
Yes 367.9 (88.3) 31 (1.5) 54 (2.5) 77 (3.6)
Healthy Eating Index 2010
Quartile 1 323.4 (91.2) 472 (29.5) 400 (23.7) 374 (22.0)
Quartile 2 334.0 (88.8) 406 (25.4) 445 (26.3) 397 (23.4)
Quartile 3 337.8 (89.1) 391 (24.5) 421 (24.9) 435 (25.6)
Quartile 4 350.3 (88.6) 329 (20.6) 425 (25.1) 492 (29.0)
Missing 527 435 433
History of cancer diagnosis
No 337.15 (90.8) 1706 (80.3) 1762 (82.9) 1843 (86.5)
Yes 318.71 (89.7) 419 (19.7) 364 (17.1) 288 (13.5)
WHI OPACH participants enrolled in 2012–2013 and followed up for cancer incidence through March 31, 2018.
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study expands on the limited published findings on cancer
outcomes and accelerometer-measured PA by showing clear and
strong evidence of lower risk of 13 cancers associated with higher
amounts of accelerometer-measured MVPA, even after controlling
for several relevant risk predictors including BMI.
A large number of observational8,9 and clinical studies33 have
reported the benefits of PA for reducing the risk of overall cancer
incidence and cancer mortality. In a meta-analysis of 126 cohort
studies, Liu et al. reported a relative risk of 0.90 for overall cancer
incidence among individuals participating in the greatest amount
of leisure-time PA (i.e., 95th percentile) as compared with those
participating in the least amount of leisure-time PA (i.e., 5th
percentile).8 In comparison, a meta-analysis by Li et al., which
included 36 population-based studies from North America, Europe
and Asia, reported a 16% decrease in cancer mortality, when
compared with individuals who were physically inactive.9 Although
these meta-analyses were able to pool data from millions of
individuals, both relied on studies that used self-reported measures
of PA, which have been shown to lack precision, often reflecting
over- or under-reporting of activities that are challenging to assess
by questionnaire,11 and fail to capture all activities performed
throughout the day. Therefore, even these exceptionally large
meta-analyses, when based on self-reported PA exposures, may not
provide an accurate representation of the true association between
PA and cancer incidence in the community.
It has long been hypothesised that engaging in PA, and
avoiding sedentary behaviour, may play an important role in
cancer prevention; however, the biological pathways regulating
this observed risk reduction are still being clarified.34,35 Various
site-specific cancers have different magnitudes of association with
Table 2. Hazard ratios (HRs) and 95% confidence intervals (CIs) for physical activity-related cancer incidence and tertiles of wear time-standardised
total, light and moderate-to-vigorous physical activity (N= 6382).
Physical activity Tertiles of PA
Total physical activity Tertiles of total PA PTrend
a
T1 (low) T2 T3 (high)
Total PA minutes per day, mean (SD) 236.0 (43.5) 331.7 (22.8) 434.1 (52.0)
Cancer events, n (%) 110 (5.2) 84 (4.0) 78 (3.7)
Person-years 9,014.17 9,518.96 9,741.07
Incidence rate per 1,000 person-years 12.20 8.82 8.01
Model 1: Hazard ratio (95% CI)b 1.00 0.73 (0.55–0.98) 0.67 (0.50–0.90) 0.01
Model 2: Hazard ratio (95% CI)c 1.00 0.78 (0.58–1.04) 0.72 (0.53–0.97) 0.03
Model 3: Hazard ratio (95% CI)d 1.00 0.80 (0.60–1.07) 0.76 (0.55–1.04) 0.10
Light physical activity Tertiles of light PA PTrend
a
T1 (low) T2 T3 (high)
Light PA minutes per day, mean (SD) 205.5 (35.8) 283.3 (18.1) 364.2 (40.9)
Cancer events, n (%) 104 (4.9) 86 (4.0) 82 (3.8)
Person-years 9092.91 9522.33 9659.0
Incidence rate per 1000 person-years 11.44 9.03 8.49
Model 1: Hazard ratio (95% CI)b 1.00 0.80 (0.60–1.07) 0.76 (0.57–1.02) 0.03
Model 2: Hazard ratio (95% CI)c 1.00 0.85 (0.63–1.13) 0.81 (0.60–1.09) 0.10
Model 3: Hazard ratio (95% CI)d 1.00 0.88 (0.66–1.19) 0.86 (0.63–1.18) 0.25
Moderate-to-vigorous physical activity Tertiles of MVPA PTrend
a
T1 (low) T2 T3 (high)
MVPA minutes per day, mean (SD) 18.3 (8.7) 43.3 (7.4) 87.4 (27.3)
Cancer events, n (%) 113 (5.3) 79 (3.7) 80 (3.8)
Person-years 8953.23 9501.14 9819.8
Incidence rate per 1000 person-years 12.62 8.31 8.15
Model 1: Hazard ratio (95% CI)b 1.00 0.66 (0.49–0.89) 0.65 (0.48–0.88) 0.02
Model 2: Hazard ratio (95% CI)c 1.00 0.67 (0.50–0.90) 0.66 (0.48–0.91) 0.03
Model 3: Hazard ratio (95% CI)d 1.00 0.68 (0.50–0.91) 0.69 (0.50–0.95) 0.05
WHI OPACH participants enrolled in 2012–2013 and followed up for cancer incidence through March 31, 2018. Women were censored at the end of follow-up,
at the last contact or at the time of death from an event unrelated to cancer.
BMI body mass index, MVPA moderate-to-vigorous physical activity, PA physical activity, SD standard deviation.
aP-values from chi-square tests for linear trend using Cox regression models with continuous PA variables.
bModel 1 is adjusted for age (years).
cModel 2 is adjusted for age (years), race/ethnicity (non-Hispanic white, non-Hispanic black and Hispanic), education (≤high school, some college and
≥college), smoking status/pack-years (never smoker, former smoker/≤7.5 or >7.5 pack-years and current smoker/≤22.5 or >22.5 pack-years), alcohol intake
(non-drinker, <1 drink per week, 1–4 drinks per week and 5–7 drinks per week), hormone replacement therapy (no, yes), self-rated general health (excellent or
very good, good, fair or poor), number of comorbid conditions (0, 1, 2, 3+), HEI-2010 (quartiles) and history of cancer diagnosis (no, yes).
dModel 3 is adjusted for age (years), race/ethnicity (non-Hispanic white, non-Hispanic black and Hispanic), education (≤high school, some college and
≥college), smoking status/pack-years (never smoker, former smoker/≤7.5 or >7.5 pack-years and current smoker/≤22.5 or >22.5 pack-years), alcohol intake
(non-drinker, <1 drink per week, 1–4 drinks per week and 5–7 drinks per week), hormone replacement therapy (no, yes), self-rated general health (excellent or
very good, good, fair or poor), number of comorbid conditions (0, 1, 2, 3+), HEI-2010 (quartiles), history of cancer diagnosis (no, yes) and BMI (<18.5, 18.5–24.9,
25.0–29.9, 30–34.9, 35–39.9 and ≥40 kg/m2).
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PA, suggesting that PA does not modulate one common pathway
to carcinogenesis, but rather affects a number of biological
processes, including metabolic profiles,34–36 hormone levels34,35,37
and immunologic functions,34,38–40 which in turn impact the risk of
cancer over an individual’s lifespan.33,35
Our stratified results, if reproducible in other populations,
suggest that PA may play a stronger role in cancer prevention in
women up to at least the age of 80, while the beneficial impact of
PA on cancer may wane at ages over 80. PA may be less effective
in protecting against the likelihood of carcinogenesis, as the
effects of oxidative stress and DNA damage continue to
accumulate over the lifespan.41,42 Moreover, the biological path-
ways that protect the body from cancer tend to operate less
efficiently with increasing age.43
The major strength of our study lies in the careful measurement
of PA using triaxial accelerometers with output precisely calibrated
to older women’s movement patterns and energy expenditure
in a laboratory substudy.16 Thus, our study provides the first
epidemiologic cohort study evidence that objectively measured
PA is inversely associated with incidence of 13 cancers in
community-dwelling older women in later life. Furthermore, the
OPACH study has detailed information on relevant characteristics
that could be related to both PA and cancer incidence, including
demographics, lifestyle behaviours, personal medical history and
anthropometric measures. The limitations of this study include the
use of a composite cancer outcome comprising a relatively small
number of incident cancer cases observed over the 4–6-year
follow-up period, which precluded examination of site-specific
cancers separately. In addition, because of the relatively short
follow-up, the role that PA plays in cancer initiation within the 4–6
years prior to diagnosis is unclear. However, while the inferences
we can make about cancer initiation may be limited, it is plausible
that some cancers could develop within this timeframe. Further-
more, PA may also impact cancer risk by inhibiting tumour
progression by, for example, suppressing tumour growth and
angiogenesis, and stimulating apoptosis.44 Thus, PA likely exerts a
combination of effects on both cancer initiation and progression,
and the relative importance of each may depend on the site-
specific cancer being considered and its inherent aggressiveness.
The associations reported here, therefore, are still relevant for
understanding how PA impacts cancer risk. Evaluation of a
composite cancer incidence outcome also makes it challenging to
ascribe biological mechanisms that might underpin the inverse
associations observed herein, as the site-specific cancers identified
during the present follow-up experience could have both shared
as well as unique mechanisms through which PA could mitigate
risk. Although our measure of PA was objective, we relied on
a single assessment of PA, and so, were not able to account
for changes in PA over time, which could be important in
disentangling the influence that PA has on cancer occurrence
from that which occult cancer potentially exerts on PA levels
proximal to diagnosis, and while PA cut points were derived from
a calibration study conducted for OPACH, the calibration study
was laboratory-based only, and did not include free-living testing.
We also acknowledge that although the accelerometer assess-
ment provides an objective assessment of PA, it is not without
limitations. Women may have altered their behaviour in response
to wearing the device; however, this would have resulted in
estimates that were biased towards the null, as it would have been
non-differential with respect to cancer incidence. In addition,
some activities such as swimming and bicycling are not well
assessed by accelerometers. In the OPACH Study, 15% of women
reported riding a bicycle or using a stationary bicycle, and 7%
of women reported swimming regularly. This underestimate of
Table 3. Hazard ratios (HR) and 95% confidence intervals (CI) for physical activity-related cancer incidence and standardised total, light and
moderate-to-vigorous physical activity in the cohort overall and among cohort subgroups (N= 6382).
Cohort group Cancer events n (%) Total PAa Light PAa MVPAa
HR (95% CI)b PInteraction
c HR (95% CI)b PInteraction
c HR (95% CI)b PInteraction
c
Overall 272 (4.3) 0.87 (0.76–0.99) 0.90 (0.79–1.02) 0.85 (0.74–0.98)
Age (years) 0.03 0.04 0.31
<80 132 (4.1) 0.75 (0.63–0.90) 0.78 (0.65–0.93) 0.79 (0.65–0.96)
≥80 140 (4.4) 0.99 (0.82–1.18) 1.01 (0.85–1.20) 0.92 (0.75–1.14)
Race/ethnicity 0.45 0.39 0.80
Non-Hispanic white 146 (4.6) 0.93 (0.77–1.11) 0.96 (0.81–1.14) 0.89 (0.73–1.08)
Non-Hispanic black 89 (4.1) 0.75 (0.60–0.94) 0.78 (0.63–0.98) 0.76 (0.58–0.99)
Hispanic/Latina 37 (3.4) 0.89 (0.62–1.27) 0.92 (0.64–1.30) 0.89 (0.63–1.26)
BMI (kg/m2) 0.38 0.20 0.81
<30 174 (4.0) 0.94 (0.80–1.11) 0.98 (0.83–1.15) 0.88 (0.74–1.04)
≥30 98 (4.8) 0.81 (0.64–1.02) 0.82 (0.65–1.02) 0.86 (0.66–1.14)
Cigarette-smoking history 0.24 0.48 0.09
Never 125 (3.6) 0.80 (0.65–0.97) 0.85 (0.70–1.02) 0.76 (0.61–0.96)
Ever 147 (5.1) 0.90 (0.75–1.07) 0.92 (0.78–1.09) 0.89 (0.74–1.08)
WHI OPACH participants enrolled in 2012–2013 and followed up for cancer incidence through March 31, 2018. Women were censored at the end of follow-up,
at the last contact or at the time of death from an event unrelated to cancer.
BMI body mass index, MVPA moderate-to-vigorous physical activity, PA physical activity.
aOne-standard deviation unit increment of total PA= 90.8 min, light PA= 72.8 min and MVPA= 33.3 min.
bModel is adjusted for age (years), race/ethnicity (non-Hispanic white, non-Hispanic black and Hispanic), education (≤high school, some college and ≥college),
smoking status/pack-years (never smoker, former smoker/≤7.5 or >7.5 pack-years and current smoker/≤22.5 or >22.5 pack-years), alcohol intake (non-drinker,
<1 drink per week, 1–4 drinks per week and 5–7 drinks per week), hormone replacement therapy (no, yes), self-rated general health (excellent or very good,
good, fair or poor), number of comorbid conditions (0, 1, 2, 3+), HEI-2010 (quartiles) and history of cancer diagnosis (no, yes), as appropriate.
cInteraction evaluated using likelihood ratio tests comparing Cox regression models with cross-product terms for continuous physical activity, and categorical
covariates to reduced models without the interaction terms.
Associations of accelerometer-measured physical activity and physical. . .
H Parada Jr et al.
6
PA is also likely to attenuate the results. In addition, there is
high correlation between device wear time and each of the
PA categories, and so it is difficult to separately estimate the
associations of each of the PA categories. However, the results of
our isotemporal substitution models suggest that statistically
replacing sedentary time with MVPA had a stronger protective
association with cancer incidence than replacing sedentary time
with light PA. Another limitation of our study is that the study
population is restricted to postmenopausal women, and thus it is
unknown whether these findings can be generalised to younger
women or men. Even so, the hazard ratio estimate of 0.66 for
cancer incidence and MVPA is within the range of hazard ratios
(0.58–0.91) reported by Moore et al. As with any observational
study, there is the possibility that our findings are biased due
to uncontrolled confounding, in particular, with regard to the
covariate information relevant to the various site-specific cancers
we included in the composite outcome variable, though, our
results are consistent with the literature published to date.
Last, although cancer diagnoses were physician-adjudicated, it is
possible that we may have missed some cancers; however, this
outcome misclassification is likely to be minimal, given the high
commitment of the women participating in the WHI Study, as
evidenced by the low proportion of women lost to follow-up, and
the high degree of adherence to the accelerometer protocols.
CONCLUSIONS
Our study supports the hypothesis that total PA, including time
spent in moderate-to-vigorous-intensity activities, plays a bene-
ficial role in the primary prevention of 13 site-specific cancers in
older women. While the U.S. Department of Health and Human
Services provides overarching PA guidelines for Americans,
currently, there is insufficient evidence on the benefits of physical
activity on cancer prevention among older adults14 whose PA
needs may differ from the general population. Because of the
known challenges to measuring PA using questionnaires, particu-
larly in older adults and women, and because of the continued
burden that cancer imparts on an aging society, if confirmed, our
findings could have important implications to future guideline
recommendations for cancer prevention in older adults.
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